Ketamine vs Psilocybin Therapy: What Patients Need to Know

The Psychedelic Therapy Landscape

Psychedelic-assisted therapy is generating enormous excitement in mental health treatment, and two substances lead the conversation: ketamine and psilocybin. Both have shown powerful potential for treating depression, anxiety, PTSD, and other conditions that resist conventional treatment. And both work, at least in part, by promoting neuroplasticity — helping the brain form new connections and break free from rigid, unhealthy patterns.

But ketamine and psilocybin are fundamentally different substances with different legal statuses, different treatment experiences, and different levels of accessibility. If you are exploring your options, understanding these differences is essential.

Legal Status: A Critical Distinction

This is the single most important practical difference between the two.

Ketamine is a legal, FDA-approved medication (as an anesthetic) that can be prescribed off-label by licensed medical providers for depression, anxiety, PTSD, and other conditions. Spravato (esketamine nasal spray) has a specific FDA approval for treatment-resistant depression. You can access ketamine therapy today through thousands of clinics and telehealth providers across the United States.

Psilocybin remains a Schedule I controlled substance under federal law, which means it is classified as having no accepted medical use and a high potential for abuse. However, the legal landscape is shifting. Oregon has implemented a supervised psilocybin services program, and Colorado has passed legislation to create a regulated access framework. A handful of cities have decriminalized psilocybin possession. The FDA has granted "Breakthrough Therapy" designation to psilocybin for treatment-resistant depression, which may accelerate the approval process.

The bottom line: ketamine therapy is legally accessible right now through established medical channels. Psilocybin therapy is available only in limited settings and locations, with broader access likely still years away.

How Each Substance Works

Ketamine

Ketamine primarily acts on the NMDA receptors in the glutamate system, the brain's main excitatory neurotransmitter pathway. By modulating glutamate signaling, ketamine triggers a cascade of downstream effects that promote the growth of new synaptic connections. This rapid neuroplasticity is believed to be a key mechanism behind ketamine's fast-acting antidepressant effects.

Ketamine also interacts with opioid receptors, GABA receptors, and other neurotransmitter systems, though the relative importance of these interactions is still being studied.

Psilocybin

Psilocybin is converted in the body to psilocin, which primarily activates serotonin 2A receptors. This activation produces the characteristic psychedelic experience and is thought to increase communication between brain networks that do not normally interact — a phenomenon researchers call "increased neural entropy." Like ketamine, psilocybin appears to promote neuroplasticity, but through a different biochemical pathway.

The Treatment Experience

Ketamine Sessions

A ketamine session typically lasts one to two and a half hours depending on the administration method. During an IV infusion, effects begin within minutes and peak around 20 to 30 minutes. The experience commonly includes feelings of floating or dissociation, altered perception of time and space, and sometimes visual imagery or dreamlike states.

Most patients remain aware that they are in a treatment setting, even if their perception is significantly altered. The experience is sometimes described as observing your thoughts from a distance. After the session, effects wear off within one to two hours.

Ketamine therapy protocols usually involve an initial series of six sessions over two to three weeks, followed by maintenance sessions as needed.

Psilocybin Sessions

A psilocybin therapy session is a much longer undertaking. The experience itself lasts four to six hours, with preparation and integration sessions adding to the overall time commitment. In clinical and supervised settings, psilocybin is typically given in one to three sessions, often spaced weeks apart.

The psilocybin experience is generally more immersive and psychologically intense than ketamine. Patients frequently report vivid visual imagery, profound emotional experiences, a sense of connection to something larger than themselves, and encounters with deeply personal memories or insights. The experience can include challenging moments — sometimes called "difficult passages" — that trained therapists help patients navigate.

A psilocybin session is typically conducted with two trained facilitators present throughout the entire experience. The setting is carefully designed, and preparation sessions help you understand what to expect.

Effectiveness

For Depression

Both substances have shown impressive results in clinical research.

Ketamine IV infusion has demonstrated response rates of 60 to 70 percent in treatment-resistant depression, with effects appearing within hours to days. Spravato has similar efficacy data from its FDA approval trials. The rapid onset is one of ketamine's greatest strengths.

Psilocybin has shown remarkable results in clinical trials, with some studies reporting that a single or two-dose protocol produced significant and lasting improvement in depression. A notable study found that psilocybin therapy was at least as effective as a leading SSRI antidepressant over six weeks, with faster onset. Some participants maintained benefits for months or even over a year after just one or two sessions.

For Anxiety

Both ketamine and psilocybin have shown promise for anxiety, including generalized anxiety and anxiety related to serious medical illness. Psilocybin has particularly strong data for existential anxiety in patients with terminal illness, where single sessions have produced lasting reductions in anxiety and depression.

Duration of Effects

This is an area where psilocybin may have a notable advantage. While ketamine's effects often require regular maintenance sessions to sustain, psilocybin's effects may last for months or longer after just one or two sessions. This difference could relate to the depth and nature of the psychological experience, though research is still clarifying the mechanisms.

Side Effects and Risks

Ketamine

• Dissociation during sessions
• Nausea and dizziness
• Temporary blood pressure elevation
• Drowsiness after treatment
• Potential for psychological dependence with frequent use
• Bladder concerns with long-term, high-frequency use (primarily seen in recreational abuse)

Psilocybin

• Intense psychological experiences that can be challenging or distressing
• Anxiety or panic during the session
• Nausea
• Headache after the session
• Temporary increases in heart rate and blood pressure
• Very rare risk of triggering prolonged psychotic episodes (primarily in individuals with predisposing conditions)
• No known physical dependence or withdrawal

Both substances have contraindications. Ketamine is not appropriate for people with uncontrolled high blood pressure, active psychosis, or certain cardiovascular conditions. See our full guide on who should not take ketamine. Psilocybin is contraindicated for individuals with a personal or family history of psychotic disorders and should not be combined with certain medications, particularly SSRIs and lithium.

Cost and Accessibility

Ketamine

• IV infusions: $400-$800 per session, initial series of 6 sessions
• Spravato: $600-$900 per session without insurance; often covered by insurance
• At-home sublingual: $150-$450 per month through telehealth providers
• Available nationwide through clinics and telehealth

Psilocybin

• Oregon supervised services: approximately $1,500-$3,500 per session (includes preparation, session, and integration)
• Clinical trials: free but limited enrollment
• Very limited geographic availability
• No insurance coverage

A Practical Comparison

Which Should You Consider?

Ketamine therapy is the practical choice right now if you need treatment that is legally accessible, widely available, and can produce rapid results. If you are dealing with severe depression, suicidal thoughts, or an urgent need for relief, ketamine's speed of action and established clinical infrastructure make it the clear frontrunner.

Psilocybin therapy may be worth exploring if you have access to a legal supervised program or clinical trial, you are drawn to a deeper psychological experience, and your situation allows for the longer time commitment that psilocybin sessions require.

For many people, the decision comes down to access. Ketamine therapy is available now, through well-established medical channels, with a growing body of evidence and an experienced clinical community. Psilocybin therapy holds enormous promise, but broader access is still on the horizon.

Whatever path you choose, working with qualified, experienced providers is essential. Both of these treatments are powerful tools, and they are most effective — and safest — when guided by professionals who understand them deeply.

References

• NIMH: Cracking the Ketamine Code — NIMH feature on ketamine research and its established role in depression treatment
• NIH: How Ketamine Relieves Symptoms of Depression — NIH research on ketamine's neuroplasticity mechanism, which shares similarities with psilocybin research
• NIMH: Depression Overview — National Institute of Mental Health guide to depression and emerging treatment approaches